ASN-90 is under clinical development by Asceneuron and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ASN-90’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ASN-90 overview
ASN-90 is under development for the treatment of Progressive Supranuclear palsy (PSP), Alzheimer’s and Parkinson’s disease. It is administered orally as a tablet. It is a small molecule act by targeting O-GlcNAcase (O-linked-beta-N-acetylglucosaminidase). It was also under development for the treatment of Primary age related tauopathy and frontotemporal dementia.
Asceneuron overview
Asceneuron is a biotechnology company that discovers and develops small molecule therapeutics for neurodegenerative diseases such as orphan tauopathies, alzheimer’s and parkinson’s diseases. The company develops chemical entities which is designed to halt abnormal protein aggregation in the brain. Its pipeline products include O-GLCNACASE inhibitors such as ASN90 which treats alzheimer’s disease and orphan tauopathy progressive supranuclear palsy (PSP) and ASN51 treats alzheimer’s disease and amyotrophic lateral sclerosis; M1 PAM which is a cognitive dysfunction in dementia. Asceneuron is headquartered in Lausanne, Switzerland.
For a complete picture of ASN-90’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
